The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients' sex

doi:10.1002/ijc.32327

	The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients' sex
	Wang, Shixiang1,2,3 ; Zhang, Jing1,2,3 ; He, Zaoke1,2,3 ; Wu, Kai 4; Liu, Xue-Song1
	2019-11-15
发表期刊	INTERNATIONAL JOURNAL OF CANCER (IF:5.7[JCR-2023],6.0[5-Year])
ISSN	0020-7136
卷号	145 期号:10 页码:2840-2849
发表状态	已发表
DOI	10.1002/ijc.32327
摘要	Immunotherapy, represented by immune checkpoint inhibitors (ICI), is transforming the treatment of cancer. However, only a fraction of patients show response to ICI, and there is an unmet need for biomarkers that will identify patients more likely to respond to ICI. Here we report that the ICI response prediction biomarker tumor mutational burden (TMB) shows significant sex differences. TMB's predictive power is significantly better for female than for male lung cancer patients. Receiver operating characteristic curve analysis was performed and the area under the curve (AUC) was reported to evaluate the predictive power of TMB in lung cancer ICI response. Hazard ratios (HR) of TMB-high vs. TMB-low patients were compared between male and female patients. Both AUC and HR differences between female and male are significant in all available independent lung cancer datasets. However, the AUC of programmed death ligand 1 (PD-L1) expression does not show a difference between female and male, suggesting TMB, but not PD-L1 expression has a better predictive power for female than for male lung cancer patients. Our study suggests significant sex differences in the performance of TMB in ICI response prediction. Future development of ICI biomarker should consider sex differences and special efforts should be paid to improve the performance of ICI predictive biomarkers for male lung cancer patients.
关键词	tumor mutational burden cancer immunotherapy immune checkpoint inhibitors lung cancer sex differences
收录类别	SCI ; SCIE
语种	英语
资助项目	Shanghai Pujiang Program[16PJ1407400]
WOS研究方向	Oncology
WOS类目	Oncology
WOS记录号	WOS:000486192300023
出版者	WILEY
WOS关键词	PD-1 BLOCKADE ; CLINICAL-RESPONSE ; SOLID TUMORS ; NIVOLUMAB ; IPILIMUMAB ; PEMBROLIZUMAB ; CHEMOTHERAPY ; RESISTANCE ; LANDSCAPE ; DOCETAXEL
原始文献类型	Article
引用统计	正在获取...
文献类型	期刊论文
条目标识符	https://kms.shanghaitech.edu.cn/handle/2MSLDSTB/80217
专题	生命科学与技术学院_硕士生生命科学与技术学院_PI研究组_刘雪松组生命科学与技术学院_博士生
通讯作者	Liu, Xue-Song
作者单位	1.ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201203, Peoples R China 2.Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, Shanghai, Peoples R China 3.Univ Chinese Acad Sci, Beijing, Peoples R China 4.Zhengzhou Univ, Affiliated Hosp 1, Dept Thorac Surg, Zhengzhou, Henan, Peoples R China
第一作者单位	生命科学与技术学院
通讯作者单位	生命科学与技术学院
第一作者的第一单位	生命科学与技术学院
推荐引用方式 GB/T 7714	Wang, Shixiang,Zhang, Jing,He, Zaoke,et al. The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients' sex[J]. INTERNATIONAL JOURNAL OF CANCER,2019,145(10):2840-2849.
APA	Wang, Shixiang,Zhang, Jing,He, Zaoke,Wu, Kai,&Liu, Xue-Song.(2019).The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients' sex.INTERNATIONAL JOURNAL OF CANCER,145(10),2840-2849.
MLA	Wang, Shixiang,et al."The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients' sex".INTERNATIONAL JOURNAL OF CANCER 145.10(2019):2840-2849.